Clinical Trial Search Results for "TIMI 14"

Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation. 1999;99:2720-32. Abstract

Gibson, C. M., Murphy, S., Menown, I. B., Sequeira, R. F., Greene, R., Van de Werf, F., Schweiger, M. J., Ghali, M., Frey, M. J., Ryan, K. A., Marble, S. J., Giugliano, R. P., Antman, E. M., Cannon, C. P., Braunwald, E. Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction J Am Coll Cardiol. 1999;34(5):1403-12. Abstract

Gibson, C. M., Ryan, K. A., Murphy, S. A., Mesley, R., Marble, S. J., Giugliano, R. P., Cannon, C. P., Antman, E. M., Braunwald, E. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction J Am Coll Cardiol. 1999;34(4):974-82. Abstract

Antman, E. M., Gibson, C. M., de Lemos, J. A., Giugliano, R. P., McCabe, C. H., Coussement, P., Menown, I., Nienaber, C. A., Rehders, T. C., Frey, M. J., Van der Wieken, R., Andresen, D., Scherer, J., Anderson, K., Van de Werf, F., Braunwald, E. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators Eur Heart J. 2000;21(23):1944-53. Abstract

Cannon, C. P. Bridging the gap with new strategies in acute ST elevation myocardial infarction: bolus thrombolysis, glycoprotein IIb/IIIa inhibitors, combination therapy, percutaneous coronary intervention, and "facilitated" PCI J Thromb Thrombolysis. 2000;9(3):235-41. Abstract

Coulter, S. A., Cannon, C. P., Ault, K. A., Antman, E. M., Van de Werf, F., Adgey, A. A., Gibson, C. M., Giugliano, R. P., Mascelli, M. A., Scherer, J., Barnathan, E. S., Braunwald, E., Kleiman, N. S. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14 Circulation. 2000;101(23):2690-5. Abstract

Llevadot, J., Giugliano, R. P., McCabe, C. H., Cannon, C. P., Antman, E. M., Murphy, S., Gibson, C. M. Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials) Am J Cardiol. 2000;85(12):1409-13. Abstract

de Lemos, J. A., Antman, E. M., Gibson, C. M., McCabe, C. H., Giugliano, R. P., Murphy, S. A., Coulter, S. A., Anderson, K., Scherer, J., Frey, M. J., Van Der Wieken, R., Van De Werf, F., Braunwald, E. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial Circulation. 2000;101(3):239-43. Abstract

de Lemos, J. A., Antman, E. M., Giugliano, R. P., McCabe, C. H., Murphy, S. A., Van de Werf, F., Gibson, C. M., Braunwald, E. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators Am J Cardiol. 2000;85(3):299-304. Abstract

de Lemos, J. A., Antman, E. M., Morrow, D. A., Llevadot, J., Giugliano, R. P., Coulter, S. A., Schuhwerk, K. C., Arslanian, S., McCabe, C. H., Gibson, C. M., Rifai, N. Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy Clin Chim Acta. 2000;298(2-Jan):85-97. Abstract

Gibson, C. M., Kirtane, A. J., Murphy, S. A., Marble, S. J., de Lemos, J. A., Antman, E. M., Braunwald, E. Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction Catheter Cardiovasc Interv. 2001;53(1):11-Jun. Abstract

Gibson, C. M., Murphy, S. A., Marble, S. J., McCabe, C. H., Antman, E. M., Cannon, C. P., Braunwald, E. Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group Am J Cardiol. 2001;87(4):450-3, A6. Abstract

Gibson, C. M., de Lemos, J. A., Murphy, S. A., Marble, S. J., McCabe, C. H., Cannon, C. P., Antman, E. M., Braunwald, E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation. 2001;103(21):2550-4. Abstract

de Lemos, J. A., Gibson, C. M., Antman, E. M., Murphy, S. A., Morrow, D. A., Schuhwerk, K. C., Schweiger, M., Coussement, P., Van de Werf, F., Braunwald, E. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial Am Heart J. 2001;141(4):592-8. Abstract

de Lemos, J. A., Morrow, D. A., Gibson, C. M., Murphy, S. A., Rifai, N., Tanasijevic, M., Giugliano, R. P., Schuhwerk, K. C., McCabe, C. H., Cannon, C. P., Antman, E. M., Braunwald, E. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy Am J Cardiol. 2001;88(4):353-8. Abstract

Angeja, B. G., Kermgard, S., Chen, M. S., McKay, M., Murphy, S. A., Antman, E. M., Cannon, C. P., Braunwald, E., Gibson, C. M. The smoker's paradox: insights from the angiographic substudies of the TIMI trials J Thromb Thrombolysis. 2002;13(3):133-9. Abstract

Angeja, B. G., de Lemos, J., Murphy, S. A., Marble, S. J., Antman, E. M., Cannon, C. P., Braunwald, E., Gibson, C. M. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy Am Heart J. 2002;144(4):649-56. Abstract

Antman, E. M., Cooper, H. A., Gibson, C. M., de Lemos, J. A., McCabe, C. H., Giugliano, R. P., Coussement, P., Murphy, S., Scherer, J., Anderson, K., Van de Werf, F., Braunwald, E. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II Eur Heart J. 2002;23(12):928-33. Abstract

Cooper, H. A., de Lemos, J. A., Morrow, D. A., Sabatine, M. S., Murphy, S. A., McCabe, C. H., Gibson, C. M., Antman, E. M., Braunwald, E. Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration Am Heart J. 2002;144(5):790-5. Abstract

Murphy, S. A., Dauterman, K., de Lemos, J. A., Kermgard, S., Antman, E. M., Braunwald, E., Gibson, C. M. Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial Am Heart J. 2003;146(1):42-7. Abstract

Kirtane, A. J., Bui, A., Murphy, S. A., Karmpaliotis, D., Kosmidou, I., Boundy, K., Rahman, A., Pinto, D. S., Aroesty, J. M., Giugliano, R. P., Cannon, C. P., Antman, E. M., Gibson, C. M. Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction J Thromb Thrombolysis. 2004;17(3):177-84. Abstract

Shimpo, M., Morrow, D. A., Weinberg, E. O., Sabatine, M. S., Murphy, S. A., Antman, E. M., Lee, R. T. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction Circulation. 2004;109(18):2186-90. Abstract